Art. 11 Regulation (EU) 2024/3169

Consultation of stakeholder organisations during joint scientific consultation

In forcesince 18 Dec 2024
1.

At any time during the joint scientific consultation on medicinal products, the JSC Subgroup, via the HTA secretariat, may seek input on the disease and therapeutic area relevant for the medicinal product from patient organisations, healthcare professional organisations or clinical and learned societies via the members of the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282, whilst respecting the confidential nature of the request for joint scientific consultation.

2.

Where the joint scientific consultation on medicinal products is carried out in parallel with the scientific advice, the HTA secretariat shall share the input referred to in paragraph 1 with the European Medicines Agency at the same time as sharing it with the JSC Subgroup.